Lipodox 50mg Injection

About

Lipodox 50mg Injection contains Liposomal Doxorubicin, an anthracycline topoisomerase II inhibitor chemotherapy agent encapsulated within specialized liposomes. This innovative formulation significantly alters the pharmacokinetic profile of doxorubicin, allowing for prolonged circulation in the bloodstream and preferential accumulation in tumor tissues due to the enhanced permeability and retention (EPR) effect. The liposomal encapsulation reduces peak plasma concentrations of free doxorubicin, thereby substantially decreasing the incidence and severity of cardiotoxicity and other systemic side effects like myelosuppression and alopecia, which are common with conventional doxorubicin. It retains the potent cytotoxic activity against various cancers by intercalating DNA, inhibiting topoisomerase II, and generating free radicals, offering an improved therapeutic index for patients.

Uses

• Treatment of ovarian cancer that has recurred or progressed after platinum-based chemotherapy.
• Treatment of AIDS-related Kaposi's sarcoma.
• Treatment of metastatic breast cancer in patients at increased cardiac risk.
• Management of multiple myeloma in combination with bortezomib.

Directions For Use

Lipodox 50mg Injection is administered intravenously by a healthcare professional. The dosage and infusion rate are determined by the patient's condition, body surface area, and treatment protocol.

Benefits

• Reduced cardiotoxicity compared to conventional doxorubicin.
• Lower incidence of myelosuppression and alopecia.
• Prolonged circulation and preferential tumor accumulation.
• Effective against various solid tumors and hematologic malignancies.
• Offers a treatment option for patients with cardiac risk factors.
• Improved safety profile while maintaining efficacy.

Side Effects

• Nausea
• Vomiting
• Stomatitis/Mucositis
• Palmar-plantar erythrodysesthesia (PPE)
• Myelosuppression (neutropenia, thrombocytopenia)
• Fatigue
• Alopecia (less common than conventional doxorubicin)
• Diarrhea
• Constipation
• Fever
• Infusion-related reactions
• Cardiotoxicity (reduced but still possible)

Safety Measures

• Alcohol - Avoid alcohol during treatment as it may exacerbate gastrointestinal side effects or interact with the medication.
• Pregnancy - Lipodox is embryotoxic, fetotoxic, and teratogenic. It is contraindicated during pregnancy. Women of childbearing potential must use effective contraception.
• Breastfeeding - Breastfeeding is contraindicated during Lipodox treatment and for a period after the last dose, due to potential serious adverse reactions in the infant.
• Liver - Dose adjustments are necessary for patients with hepatic impairment. Monitor liver function tests closely before and during treatment.
• Kidney - No specific dose adjustments are generally required for renal impairment, but caution is advised. Monitor kidney function.
• Lung - Rare cases of pneumonitis have been reported. Monitor for new or worsening respiratory symptoms, especially in patients with pre-existing lung conditions.

Disclaimer

MedEHub is committed to delivering reliable, expert-reviewd information to help consumers make informed health decisions. However, the content provided on this website is for informational purposes only and is not intended to replace professional medical advice, diagnosis or treatment.

Always consult your doctor for any medical concerns, and discuss your questions about health conditions or medications with a qualified healthcare professional. Do not ignore or delay seeking professional medical advice based on information found on Med E Hub.

Our goal is to complement, not replace, the essential doctor-patient relationship.